CAM
ITOS

ClariVest Asset Management’s iTeos Therapeutics ITOS Stock Holding History

ClariVest Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,255
Closed -$467K – 808
2023
Q2 		$467K Buy
35,255
+16,623
+89% +$237K 0.02% 355
2023
Q1 		$254K Sell
18,632
-68
-0.4% -$1.22K 0.01% 417
2022
Q4 		$366K Sell
18,700
-300
-2% -$5.86K 0.02% 403
2022
Q3 		$362K Hold
19,000
– – 0.02% 395
2022
Q2 		$392K Buy
+19,000
New +$451K 0.02% 408

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ClariVest Asset Management's ITOS Position: Q3 2023 in Review

ClariVest Asset Management sold out of iTeos Therapeutics (ITOS) in Q3 2023, closing a stake of 35,255 shares — an estimated $467K sold.

ClariVest Asset Management first reported a position in ITOS in Q2 2022 and held it in 5 quarters. The position peaked at $467K in Q2 2023. 144 funds tracked by Wall St. Rank hold ITOS as of Q3 2023.

  • ClariVest Asset Management reported no remaining iTeos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • ClariVest Asset Management sold 35,255 iTeos Therapeutics shares in Q3 2023, an estimated $467K.
  • ClariVest Asset Management first reported a position in iTeos Therapeutics in Q2 2022 and held it in 5 quarters.
  • ClariVest Asset Management's iTeos Therapeutics position peaked at $467K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2023.

Based on ClariVest Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.